RecruitingPhase 3NCT05659381
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Studying OBSOLETE: Primary peritoneal serous/papillary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GOG Foundation
- Principal Investigator
- Leslie Randall, MDGOG Foundation
- Intervention
- Cisplatin(drug)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2024 – 2034
Study locations (30)
- City of Hope, Duarte, California, United States
- University of California San Diego Moores Cancer Center, La Jolla, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- Stanford Ambulatory Surgery Center Lane Operating Room, Palo Alto, California, United States
- Stanford Women's Cancer Center, Palo Alto, California, United States
- Stanford Hospital, Palo Alto, California, United States
- University of Colorado Hospital - Anshutz Cancer Pavilion, Aurora, Colorado, United States
- Smilow Cancer Hospital at Yale- New Haven, New Haven, Connecticut, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables, Florida, United States
- University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach, Florida, United States
- University of Miami Hospital and Clinics, Miami, Florida, United States
- Miami Cancer Institute, Miami, Florida, United States
- Sylvester Comprehensive Cancer Center - Plantation, Plantation, Florida, United States
- University of Kansas Hospital, Kansas City, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05659381 on ClinicalTrials.govOther trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian CancerSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGPHASE2NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesAbbVie
- RECRUITINGNANCT06969833Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaCentre Oscar Lambret
- RECRUITINGNANCT05597683Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal ChemotherapyGangnam Severance Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerAbbVie
- RECRUITINGPHASE3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux Corporation
- ACTIVE NOT RECRUITINGPHASE2NCT05406674Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian CancerThe Netherlands Cancer Institute
See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →